Posted by Adam Awdish on
Pooled Human Serum Off The Clot from Innovative Research was used in the following study:
Jee Hong Kim, Yun Young Cho, Ji Young Choi, Yu Mi Wi, and Kwan Soo Ko
July 26, 2021
In South Korea in 2010, the emergence of carbapenemase-producing Gram-negative bacteria caused serious therapeutic concern and challenges. In particular, Klebsiella pneumoniae, which produces K. pneumoniae carbapenemase (KPC), has proven to be one of the most threatening of these carbapenem resistance determinants in clinical settings. This is because K. pneumoniae is difficult to control and, without quick and coordinated intervention, often leads to outbreaks after initially emerging in a population.
A single locus variant of ST258, known as ST11, has been the most common K. pneumoniae isolate responsible for producing KPC. Recently, however, K. pneumoniae clone ST307 has also been identified as a main KPC-producing isolate. In this study, researchers compared the characteristics of these two clones regarding their antimicrobial resistance, plasmids, serotypes, and virulence. Results indicate that ST11 may be a more virulent clone than ST307, however the changes in major KPC-producing K. pneumoniae isolates seen over time warrants the need for continued observation of this bacteria and its clones.
Related products available from Innovative Research also include: